In metastatic melanoma, eIF4F has been identified as a driver of resistance to therapies targeting BRAF and MEK, and simultaneous inhibition of BRAF and eIF4F activity synergized in killing tumor cells (10). This evidence concerns the gene BRAF and metastatic melanoma.